CRS-207 clinical trials
Also written CRS-207.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses CRS-207 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CRS-207
- 8
Studies by the year they started
9 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
Aduro Biotech, Inc. (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Anza Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CRS-207 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05014776Written as CRS-207How we know
- Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03190265Written as CRS-207How we know
- GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02243371Written as CRS-207How we know
- Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural MesotheliomaCompletedPhase 1Aduro Biotech, Inc.NCT01675765Written as Immunotherapy plus chemotherapyHow we know
- Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal CancersTerminatedPhase 2Aduro Biotech, Inc.NCT03122548Written as CRS-207How we know
- Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)TerminatedPhase 2Aduro Biotech, Inc.NCT03175172Written as CRS-207How we know
- Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal CancerTerminatedPhase 1/2Aduro Biotech, Inc.NCT02575807Written as CRS-207How we know
- Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer SettingCompletedPhase 2Aduro Biotech, Inc.NCT02004262Written as CRS-207How we know
- Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard TreatmentTerminatedPhase 1Anza Therapeutics, Inc.NCT00585845Written as CRS-207, Live-attenuated Listeria monocytogenes expressing human MesothelinHow we know
Given beside what is tested · 2 — CRS-207 is usual care or a partner of the new treatment
- Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03006302Written as CRS-207How we know
- Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic CancerCompletedPhase 2Aduro Biotech, Inc.NCT01417000Written as CRS-207How we know
Codes
What other systems call CRS-207 · ClinicalTrials.gg INT016954
- UNII (FDA) JJX4JHS4POCRS-207One source FDA
- NCI Thesaurus C74055Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JJX4JHS4PO | CRS-207 | One source FDA |
| NCI Thesaurus | C74055 | Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.